Recipharm has announced it is considering the discontinuance of operations at its solid dose manufacturing facility in Ashton-under-Lyne, UK. The decision to initiate this process has been taken following a strategic review of the operation which has not been profitable for several years. The facility employs approximately 140 people. As part of this activity, appropriate consultation with employees will now commence. Recipharm will also discuss with clients the potential to transfer manu...